Oral contraceptives and the risk of gallbladder disease: a comparative safety study

Etminan, Manyar; Delaney, Joseph A. C.; Bressler, Brian; Brophy, James M.
May 2011
CMAJ: Canadian Medical Association Journal;5/17/2011, Vol. 183 Issue 8, p899
Academic Journal
Background: Recent concerns have been raised about the risk of gallbladder disease associated with the use of drospirenone, a fourth-generation progestin used in oral contraceptives. We conducted a study to determine the magnitude of this risk compared with other formulations of oral contraceptives. Methods: We conducted a retrospective cohort study using the IMS LifeLink Health Plan Claims Database. We included women who were using an oral contraceptive containing ethinyl estradiol combined with a progestin during 1997-2009. To be eligible, women had to have been taking the oral contraceptive continuously for at least six months. We computed adjusted rate ratios (RRs) for gallbladder disease using a Cox proportional hazards model. In the primary analysis, gallbladder disease was defined as cholecystectomy; in a secondary analysis, it was defined as hospital admission secondary to gallbladder disease. Results: We included 2 721 014 women in the cohort, 27 087 of whom underwent surgical or laparoscopic cholecystectomy during the follow-up period. Compared with levonorgestrel, an older second-generation progestin, a small, statistically significant increase in the risk of gallbladder disease was associated with desogestrel (adjusted RR 1.05, 95% confidence interval [CI] 1.01-1.09), drospirenone (adjusted RR 1.20, 95% CI 1.16-1.26) and norethindrone (adjusted RR 1.10, 95% CI 1.06-1.14). No statistically significant increase in risk was associated with the other formulations of oral contraceptive (ethynodiol diacetate, norgestrel and norgestimate). Interpretation: In a large cohort of women using oral contraceptives, we found a small, statistically significant increase in the risk of gallbladder disease associated with desogestrel, drospirenone and norethindrone compared with levonorgestrel. However, the small effect sizes compounded with the possibility of residual biases in this observational study make it unlikely that these differences are clinically significant.


Related Articles

  • Ethinylestradiol/norethisterone.  // Reactions Weekly;7/30/2011, Issue 1362, p15 

    The article describes the case of a 68-year-old man with Rendu-Osler disease who developed decreased libido and hypogonadism after receiving ethinylestradiol/norethisterone for the treatment of severe anaemia.

  • Predicting hospital admission and discharge with symptom or function scores in patients with schizophrenia: pooled analysis of a clinical trial extension. Kozma, Chris M.; Dirani, Riad G.; Canuso, Carla M.; Mao, Lian // Annals of General Psychiatry;2010, Vol. 9, p24 

    Background: The purpose of this analysis was to evaluate relationships between hospital admission or discharge and scores for symptom or functioning in patients with schizophrenia. Methods: Data were from three 52-week open-label extensions of the double-blind pivotal trials of paliperidone...

  • Ethinylestradiol/levonorgestrel.  // Reactions Weekly;7/20/2013, Issue 1462, p21 

    The article presents a case study about the development of peripheral arterial disease in a 40-year-old woman after receiving ethinyl estradio/loevonorgestrel.

  • Ethinylestradiol/etonogestrel.  // Reactions Weekly;10/29/2016, Vol. 1625 Issue 1, p98 

    The article presents a case study of a 18-year-old-woman admitted due five days of worsening intermittent periumbilical, epigastric and right upper quadrant (RUQ) abdominal pain, who developed acute mesenteric venous thrombosis (MVT) while using ethinylestradiol/etonogestrel vaginal ring.

  • Hospitalizations for medication conditions on the rise among Americans ages 45 and older.  // Healthcare Purchasing News;Dec2010, Vol. 34 Issue 12, p16 

    The article discusses a report which was released by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality and which indicates that the number of hospital admissions among Americans ages 45 and older for medication and drug-related conditions doubled...

  • Hospitalisations for ADRs "substantial" among US elderly.  // Reactions Weekly;12/3/2011, Issue 1380, p3 

    The article discusses research by D. S. Budnitz et al, published in the November 2011 issue of the "New England Journal of Medicine" which estimated that 99,628 emergency hospitalisations for adverse drug events emerge yearly among older adults in the U.S.

  • Deaths from adverse drug reactions on the rise over ten years.  // Nursing Standard;7/7/2010, Vol. 24 Issue 44, p17 

    An abstract of the article “Ten-year trends in hospital admissions for adverse drug reactions in England: 1999-2009,” by T-Y Wu and others is presented.

  • A Randomized, Controlled, Multicenter Clinical Trial Comparing Pemetrexed/Cisplatin and Gemcitabine/Cisplatin as First-line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer. Yan Huang; Yunpeng Liu; Jianying Zhou; Nong Xu; Baolan Li; Gang Wu; Jian Fang; Kai Li; Xiaoqing Liu; Wei Liu; You Lu; Mengzhao Wang; Wenchao Liu; Houjie Liang; Yiping Zhang; Cheng Huang; Shunjin Wang; Yajie Wang; Shiying Yu; Jianhua Chang // Chinese Journal of Lung Cancer;Oct2012, Vol. 15 Issue 10, p576 

    Background and objective Platinum-based doublet chemotherapy is still the standard first-line treatment for non-small cell lung cancer (NSCLC). Previous studies have demonstrated that pemetrexed combined with platinum had promising efficacy and safety profile in NSCLC, especially in patients...

  • Differences in 5-year survival after a 'homeless' or 'housed' drugs-related hospital admission: a study of 15-30-year olds in Scotland. Dibben, C.; Atherton, I.; Doherty, J.; Baldacchino, A. // Journal of Epidemiology & Community Health;Sep2011, Vol. 65 Issue 9, p780 

    Background Young drug misusers and the homeless both have a greater risk of death than their peers. This study sought to estimate the additional impact of homelessness on the risk of death for young drugs misusers. Methods From all admissions to NHS hospitals in Scotland between 1986 and 2001,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics